Lung Cancer Flashcards

1
Q

At what size does a pulmonary nodule require a Brock Score Performing?

A

GREATER than or EQUAL TO 8mm or 300mm3 on volumetry

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the measurement criteria for a nodule to require follow up?

A

GREATER or EQUAL to 5mm or 80mm3. If 5-6mm then requires follow up scan at 1 year. If 6-8mm or 80mm3 then needs follow up at 3 months.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the first line chemotherapy for patients with locally advanced/metastatic non-SCLC with EGFR+ mutations?

A

Gefitinib as per NICE recommendations.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Which positive tumour markers would you expect to see in an adenocarcinoma?

A

TTF-1
CK 7
Napsin A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Which positive tumour markers would you expect to see in a squamous cell lung cancer?

A

CK5
CK6
p63
TTF-1 negative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which positive tumour markers would you expect to see in a Small Cell lung cancer?

A

TTF-1
Neuroendocrine markers e.g.
CD56, synaptophysin, chromogranin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

When can Pembrolizumab be used as first line chemotherapy?

A

If confirmed NSCLC and PD-L1 expression is >50% with NEGATIVE ALK and EGFR mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the median survival time of a patient with malignant mesothelioma following diagnosis?

A

9.5 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

At what level of lidocaine usage during bronchoscopy may a patient develop toxicity?

A

> 9.6mg/kg
Although doses of up to 15.4 mg/kg may be used without adverse effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the treatment of choice for limited stage SMALL CELL lung cancer?

A

First line is cisplatin-based chemotherapy. This is usually with concurrent radiotherapy if it can be encompassed in a field and WHO 0-1.
If unfit for concurrent therapy then can consider sequential chemotherapy and radiotherapy if the tumour responds to chemo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

When is carboplatin used in treatment of mesothelioma?

A

Cisplatin-based combination chemotherapy is first line. If this cannot be tolerated then carboplatin can be substituted.
Usually if RENAL IMPAIRMENT, WHO 2+ or significant comorbidities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

When should prophylactic cranial irradiation be offered in small cell lung cancer? What is the dose?

A

If a patient has Performance Status 0-2 with LIMITED STAGE disease that has NOT PROGRESSED on first line treatment.
The dose is 25 Gy in 10 fractions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

In which demographics are EGFR mutations more common?

A

Females, non-smokers and those of Asian-Pacific descent.
Most common in non-small cell tumours with adenocarcinoma differentiation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which antibodies are associated with neurological syndromes in lung cancer patients?
Which type of lung cancer are they associated with?

A

Anti-Hu antibodies.
Associated with small cell lung cancer.
Can cause symptoms such as limbic encephalitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How many lung segments are there? How are they distributed?

A

19 in total
10 right, 9 left
3 RUL
2 RML
5 RLL
3 LUL
2 Lingula
4 LLL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the components of the Lent score and how are they scored?

A

LDH- from pleural fluid
<1500 = 0, >1500 =1
ECOG Performance Status
0 = 0, 1 = 1, 2 = 2, 3/4 =3
Neutrophil:Lymphocyte Ratio (Pleural Fluid)
<9 = 0, >9 = 1
Tumour Type
Mesothelioma, Haematological = 0
Breast, Gynae, Renal = 1
Lung cancer, Other = 2

0-1 = Low Risk (319 day med survival)
2-4 = Medium Risk (130 days)
5-7 = High risk (44 day median)

17
Q

In what size of tumour can SABR be used?

A

LESS THAN OR EQUAL TO 5cm

18
Q

A patient has begun chemotherapy for metastatic lung cancer but developed an acneiform rash, what is the most likely causative agent?

A

Erlotinib- causes an acneiform rash in around 2/3 of patients
Development of rash is thought to be associated with better prognosis.

19
Q

At what predicted post-op FEV1 (%) would pre-op assessment with CPET be recommended?
What is a satisfactory CPET result?

A

If predicted post-op FEV1 is LESS THAN 30% then CPET and other investigations are required.
A CPET result of >15ml/kg/min is considered satisfactory

20
Q

What is the indication for pembrolizumab as 1st line immunotherapy?
What are common/possible side effects?

A

In NON-SMALL CELL cancers with
PD-L1 expression >50% and NEGATIVE EGFR and ALK mutations
Side effects include nausea, diarrhoea, fatigue and pyrexia but it can also cause immunotherapy-related hypophysitis (inflammation of the pituitary gland): Hypocortisolism, hypothyroidism and hypogonadism

21
Q

What is the first line treatment for non-squamous NSCLC with ROS-1 mutation?

A

Crizotinib is 1st line.

22
Q

When is osimertinib used in the treatment of lung cancer?

A

Indicated in EGFR T790M mutation cancer where there is disease progression after first line treatment with erlotinib or gefitinib

23
Q

What is Lambert-Eaton Myaesthenic syndrome? With which cancer and which antibodies is it associated?

A

Paraneoplastic phenomenon usually presenting with proximal muscle weakness that improves with repetition of the exercise.
Often associated with small cell lung cancer.
Associated with antibodies vs voltage-gated calcium channels

24
Q

What are the chemotherapy agents that may be used in ALK POSITIVE mutations?

A

Alectinib, Ceritinib and Crizotinib

25
Q

What is the median survival of limited stage SMALL CELL lung cancer treated with chemotherapy?

A

15-20 months

26
Q

What is the 30-day mortality rate for lobectomy and pneumonectomy respectively?

A

2.3% for lobectomy
5.8% for pneumonectomy
Individual risk can be calculated with thoracoscore

27
Q

What is the recommended first line imaging in patients with localised signs or symptoms of bone mets?

A

X-ray should be the first line imaging.
If inconclusive then can consider a bone scan or MRI.
Urgent MRI is required if suspected spinal cord compression

28
Q

What is the most appropriate initial treatment in malignant spinal cord compression?

A

Dexamethasone (16mg if oral) or equivalent IV
To continue with a dose of 16mg daily until surgery or other treatment can be initiated

29
Q

What are the Herder score cut off points in investigating lung cancer?

A

<10% should continue on the monitoring algorithm
10-70% should consider image-guided biopsy, excision biopsy or CT surveillance depending upon patient preference
>70% should consider excision biopsy or non-surgical management

30
Q

What are the first-line options available for chemotherapy in malignant mesothelioma? What are the requirements?

A

First line options are either CISPLATIN-PERMETREXED chemotherapy or NIVOLUMAB-IPILIMUMAB in patients with performance status 0-1.
Bevacizumab may be added in
NIVOLUMAB-IPILIMUMAB is first line treatment of choice if good performance status

31
Q

Which type of mediastinal mass may show Antoni A and Antoni B regions on histology?

A

Schwannoma.
May present as a posterior mediastinal mass

32
Q

What grading system is used in the classification of thymoma?

A

Masaoka-Koga classification system
3 main stages
1: Completely encapsulated tumour
2: Macroscopic invasion into surrounding fatty tissue or adhered to but not invading the mediastinum
3: Macroscopically invading into adjacent structures e.g. pericardium/great vessels/lung

33
Q

What grading system is used in the classification of teratoma?

A

Gonzalez-Crussi grading system

34
Q

What is the median survival for Stage IVA lung cancer?